Figure 4. Association of plasma PCTK1 mRNA levels with patient survival. Kaplan-Meier plots of progression-free survival (PFS) (A) and overall survival (OS) (B) for patients with different plasma PCTK1 mRNA levels (PCTK1-high and PCTK1-low). The median PFS was 5.5 (95%CI=4.5-6.6) months and 14.3 (95%CI=0.7-27.8) months in the PCTK1-high and PCTK1-low groups, respectively; the median OS was 22.7 (95%CI=10.3-35.1) months and 55.5 (95%CI= 28-83) months, respectively.